Skip to main content
SpringerLink
Log in

Nerve Growth Factor and Neuropathic Pain

  • Chapter
  • First Online:
Pathogenesis of Neuropathic Pain

  • 691 Accesses

Abstract

Nerve growth factor is probably the best studied of all the neurotrophins or neuronal growth factors. These all bind with varying degrees of specifically to NT receptors. The expression of NGF afternoon acute insult and subsequent hyperexcitability is a common pathway that we likely observe in the development of neuropathic pain syndromes. NGF signaling is mediated via binding at the p75NTR and TrkA receptor with the TrkA receptor exhibiting picomolar affinity and selectivity to NGF in the presence of other neurotrophins. NGF binding at the p75NTR receptor may result in either apoptosis or cell survival pathways. The binding of NGF to TrkA is thought to be responsible for neuronal survival and neuronal differentiation. When NGF is dysregulated neuropathic pain results and augmented neurite outgrowth with concomitant nociceptor sensitivity occurs. NGF plays critical roles in mediation of inflammation, the development of neuropathy, CNS-mediated analgesia in diabetic neuropathy, the development and maintenance of sensory neurons, the promotion of sensory and sympathetic neuronal survival; and the mediation of pain. Molecular as well as genetic interventions have been developed which target the interaction of NGF and the TrkA receptor. This chapter focuses upon these roles in a number of neuropathic syndromes and therapeutic approaches to neuropathic pain mediated by NGF.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kobayashi H, Yamada Y, Morioka S, et al. Mechanism of pain generation for endometriosis-associated pelvic pain. Arch Gynecol Obstet. 2014;289(1):13–21.

    Article  CAS  PubMed  Google Scholar 

  2. Levi-Montalcini R, Hamburger V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool. 1951;116(2):321–61.

    Article  CAS  PubMed  Google Scholar 

  3. Mantyh PW, Koltzenburg M, Mendell LM, et al. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology. 2011;115(1):189–204.

    Article  PubMed  Google Scholar 

  4. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N Engl J Med. 2010;363(16):1521–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Fahnestock M, Yu G, Michalski B, et al. The nerve growth factor precursor proNGF exhibits neurotrophic activity but is less active than mature nerve growth factor. J Neurochem. 2004;89(3):581–92.

    Article  CAS  PubMed  Google Scholar 

  6. Pattarawarapan M, Burgess K. Molecular basis of neurotrophin-receptor interactions. J Med Chem. 2003;46(25):5277–91.

    Article  CAS  PubMed  Google Scholar 

  7. Wehrman T, He X, Raab B, et al. Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors. Neuron. 2007;53(1):25–38.

    Article  CAS  PubMed  Google Scholar 

  8. Hempstead BL. The many faces of p75NTR. Curr Opin Neurobiol. 2002;12(3):260–7.

    Article  CAS  PubMed  Google Scholar 

  9. Clewes O, Fahey MS, Tyler SJ, et al. Human ProNGF: biological effects and binding profiles at TrkA, P75NTR and sortilin. J Neurochem. 2008;107(4):1124–35.

    CAS  PubMed  Google Scholar 

  10. Deppmann CD, Mihalas S, Sharma N, et al. A model for neuronal competition during development. Science. 2008;320(5874):369–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zhao J, Seereeram A, Nassar MA, et al. Nociceptor-derived brain-derived neurotrophic factor regulates acute and inflammatory but not neuropathic pain. Mol Cell Neurosci. 2006;31(3):539–48.

    Article  CAS  PubMed  Google Scholar 

  12. Lu SH, Yang Y, Liu SJ. An investigation on the division of neuronal PC12 cells induced by nerve growth factor. Sheng Li Xue Bao. 2005;57(5):552–6.

    CAS  PubMed  Google Scholar 

  13. Shaqura M, Khalefa BI, Shakibaei M, et al. New insights into mechanisms of opioid inhibitory effects on capsaicin-induced TRPV1 activity during painful diabetic neuropathy. Neuropharmacology. 2014;85:142–50.

    Article  CAS  PubMed  Google Scholar 

  14. Mousa SA, Cheppudira BP, Shaqura M, et al. Nerve growth factor governs the enhanced ability of opioids to suppress inflammatory pain. Brain. 2007;130(Pt 2):502–13.

    Article  PubMed  Google Scholar 

  15. Chang DS, Hsu E, Hottinger DG, et al. Anti-nerve growth factor in pain management: current evidence. J Pain Res. 2016;9:373–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Schafers M, Svensson CI, Sommer C, et al. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci. 2003;23(7):2517–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Obata K, Yamanaka H, Dai Y, et al. Activation of extracellular signal-regulated protein kinase in the dorsal root ganglion following inflammation near the nerve cell body. Neuroscience. 2004;126(4):1011–21.

    Article  CAS  PubMed  Google Scholar 

  18. Jin X, Gereau RWT. Acute p38-mediated modulation of tetrodotoxin-resistant sodium channels in mouse sensory neurons by tumor necrosis factor-alpha. J Neurosci. 2006;26(1):246–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Binshtok AM, Wang H, Zimmermann K, et al. Nociceptors are interleukin-1beta sensors. J Neurosci. 2008;28(52):14062–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Costa R, Bicca MA, Manjavachi MN, et al. Kinin receptors sensitize TRPV4 channel and induce mechanical hyperalgesia: relevance to paclitaxel-induced peripheral neuropathy in mice. Mol Neurobiol. 2018;55(3):2150–61.

    Article  CAS  PubMed  Google Scholar 

  21. Skoff AM, Resta C, Swamydas M, et al. Nerve growth factor (NGF) and glial cell line-derived neurotrophic factor (GDNF) regulate substance P release in adult spinal sensory neurons. Neurochem Res. 2003;28(6):847–54.

    Article  CAS  PubMed  Google Scholar 

  22. Mantyh PW. Neurobiology of substance P and the NK1 receptor. J Clin Psychiatry. 2002;63(Suppl 11):6–10.

    CAS  PubMed  Google Scholar 

  23. Mashaghi A, Marmalidou A, Tehrani M, et al. Neuropeptide substance P and the immune response. Cell Mol Life Sci. 2016;73(22):4249–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Goettl VM, Hussain SR, Alzate O, et al. Differential change in mRNA expression of p75 and Trk neurotrophin receptors in nucleus gracilis after spinal nerve ligation in the rat. Exp Neurol. 2004;187(2):533–6.

    Article  CAS  PubMed  Google Scholar 

  25. McMahon SB, Cafferty WB, Marchand F. Immune and glial cell factors as pain mediators and modulators. Exp Neurol. 2005;192(2):444–62.

    Article  CAS  PubMed  Google Scholar 

  26. McMahon SB, Cafferty WB. Neurotrophic influences on neuropathic pain. Novartis Found Symp. 2004;261:68–92; discussion 92–102, 149–54.

    CAS  PubMed  Google Scholar 

  27. Woolf CJ, Shortland P, Reynolds M, et al. Reorganization of central terminals of myelinated primary afferents in the rat dorsal horn following peripheral axotomy. J Comp Neurol. 1995;360(1):121–34.

    Article  CAS  PubMed  Google Scholar 

  28. Pollock J, McFarlane SM, Connell MC, et al. TNF-alpha receptors simultaneously activate Ca2+ mobilisation and stress kinases in cultured sensory neurones. Neuropharmacology. 2002;42(1):93–106.

    Article  CAS  PubMed  Google Scholar 

  29. Gardiner NJ, Cafferty WB, Slack SE, et al. Expression of gp130 and leukaemia inhibitory factor receptor subunits in adult rat sensory neurones: regulation by nerve injury. J Neurochem. 2002;83(1):100–9.

    Article  CAS  PubMed  Google Scholar 

  30. Kagan BL, Baldwin RL, Munoz D, et al. Formation of ion-permeable channels by tumor necrosis factor-alpha. Science. 1992;255(5050):1427–30.

    Article  CAS  PubMed  Google Scholar 

  31. Silver IA, Murrills RJ, Etherington DJ. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp Cell Res. 1988;175(2):266–76.

    Article  CAS  PubMed  Google Scholar 

  32. Einarsdottir E, Carlsson A, Minde J, Toolanen G, Svensson O, Solders G, Holmgren G, Holmberg D, Holmberg M. A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception. Hum. Mol. Genet. 2004;13(8):799–805. https://doi.org/10.1093/hmg/ddh096.

  33. Wang WB, Cao YJ, Lyu SS, et al. Identification of a novel mutation of the NTRK1 gene in patients with congenital insensitivity to pain with anhidrosis (CIPA). Gene. 2018;679:253–9.

    Article  CAS  PubMed  Google Scholar 

  34. Carvalho OP, Thornton GK, Hertecant J, et al. A novel NGF mutation clarifies the molecular mechanism and extends the phenotypic spectrum of the HSAN5 neuropathy. J Med Genet. 2011;48(2):131–5.

    Article  CAS  PubMed  Google Scholar 

  35. Capsoni S. From genes to pain: nerve growth factor and hereditary sensory and autonomic neuropathy type V. Eur J Neurosci. 2014;39(3):392–400.

    Article  PubMed  Google Scholar 

  36. Tomlinson DR, Fernyhough P, Diemel LT. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes. 1997;46(Suppl 2):S43–9.

    Article  CAS  PubMed  Google Scholar 

  37. Zherebitskaya E, Akude E, Smith DR, et al. Development of selective axonopathy in adult sensory neurons isolated from diabetic rats: role of glucose-induced oxidative stress. Diabetes. 2009;58(6):1356–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Schmidt RE, Dorsey DA, Beaudet LN, et al. Effect of NGF and neurotrophin-3 treatment on experimental diabetic autonomic neuropathy. J Neuropathol Exp Neurol. 2001;60(3):263–73.

    Article  CAS  PubMed  Google Scholar 

  39. Nct, Effects of low level laser therapy on functional capacity and DNA damage of patients with chronic kidney failure. Https://clinicaltrialsgov/show/nct03250715, 2017.

  40. Evans RJ, Moldwin RM, Cossons N, et al. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011;185(5):1716–21.

    Article  CAS  PubMed  Google Scholar 

  41. Gao Z, Feng Y, Ju H. The different dynamic changes of nerve growth factor in the dorsal horn and dorsal root ganglion leads to hyperalgesia and allodynia in diabetic neuropathic pain. Pain Physician. 2017;20(4):E551–e561.

    PubMed  Google Scholar 

  42. Choi K, Le T, Xing G, et al. Analysis of kinase gene expression in the frontal cortex of suicide victims: implications of fear and stress. Front Behav Neurosci. 2011;5:46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Manni L, Florenzano F, Aloe L. Electroacupuncture counteracts the development of thermal hyperalgesia and the alteration of nerve growth factor and sensory neuromodulators induced by streptozotocin in adult rats. Diabetologia. 2011;54(7):1900–8.

    Article  CAS  PubMed  Google Scholar 

  44. Deising S, Weinkauf B, Blunk J, et al. NGF-evoked sensitization of muscle fascia nociceptors in humans. Pain. 2012;153(8):1673–9.

    Article  CAS  PubMed  Google Scholar 

  45. Hayashi K, Shiozawa S, Ozaki N, et al. Repeated intramuscular injections of nerve growth factor induced progressive muscle hyperalgesia, facilitated temporal summation, and expanded pain areas. Pain. 2013;154(11):2344–52.

    Article  CAS  PubMed  Google Scholar 

  46. Irving G. The role of the skin in peripheral neuropathic pain. Eur J Pain Suppl. 2010;4:157–60.

    Article  CAS  Google Scholar 

  47. Hirth M, Rukwied R, Gromann A, et al. Nerve growth factor induces sensitization of nociceptors without evidence for increased intraepidermal nerve fiber density. Pain. 2013;154(11):2500–11.

    Article  CAS  PubMed  Google Scholar 

  48. Krock E, Rosenzweig AJ, Chabot-Dore P, et al. Degenerating and painful human intervertebral discs release pronociceptive factors and increase neurite sprouting and CGRP via nerve growth factor. Global Spine J. 2014; https://doi.org/10.1055/s-0034-1376539.

  49. Wuertz K, Haglund L. Inflammatory mediators in intervertebral disk degeneration and discogenic pain. Global Spine J. 2013;3(3):175–84.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Smith DI, Aziz SR, Umeozulu SN, Tran HT. Pressure-induced neuropathy and resultant pain: is a specific therapy indicated? A systematic review of the literature. Curr Neurobiol. 2019;10(3):155–70.

    Google Scholar 

  51. Pinto R, Lopes T, Frias B, et al. Trigonal injection of botulinum toxin a in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol. 2010;58(3):360–5.

    Article  CAS  PubMed  Google Scholar 

  52. Watanabe T, Inoue M, Sasaki K, et al. Nerve growth factor level in the prostatic fluid of patients with chronic prostatitis/chronic pelvic pain syndrome is correlated with symptom severity and response to treatment. BJU Int. 2011;108(2):248–51.

    Article  CAS  PubMed  Google Scholar 

  53. Kuo YC, Kuo HC. The urodynamic characteristics and prognostic factors of patients with interstitial cystitis/bladder pain syndrome. Int J Clin Pract. 2013;67(9):863–9.

    Article  PubMed  Google Scholar 

  54. Halvorson KG, Kubota K, Sevcik MA, et al. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res. 2005;65(20):9426–35.

    Article  CAS  PubMed  Google Scholar 

  55. Castaneda-Corral G, Jimenez-Andrade JM, Bloom AP, et al. The majority of myelinated and unmyelinated sensory nerve fibers that innervate bone express the tropomyosin receptor kinase A. Neuroscience. 2011;178:196–207.

    Article  CAS  PubMed  Google Scholar 

  56. Kitamura N, Nagami E, Matsushita Y, et al. Constitutive activity of transient receptor potential vanilloid type 1 triggers spontaneous firing in nerve growth factor-treated dorsal root ganglion neurons of rats. IBRO Rep. 2018;5:33–42.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Buehlmann D, Ielacqua GD, Xandry J, et al. Prospective administration of anti-nerve growth factor treatment effectively suppresses functional connectivity alterations after cancer-induced bone pain in mice. Pain. 2019;160(1):151–9.

    Article  CAS  PubMed  Google Scholar 

  58. Mantyh WG, Jimenez-Andrade JM, Stake JI, et al. Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain. Neuroscience. 2010;171(2):588–98.

    Article  CAS  PubMed  Google Scholar 

  59. Jimenez-Andrade JM, Bloom AP, Stake JI, et al. Pathological sprouting of adult nociceptors in chronic prostate cancer-induced bone pain. J Neurosci. 2010;30(44):14649–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Pantano F, Zoccoli A, Iuliani M, et al. New targets, new drugs for metastatic bone pain: a new philosophy. Expert Opin Emerg Drugs. 2011;16(3):403–5.

    Article  CAS  PubMed  Google Scholar 

  61. Jimenez-Andrade JM, Ghilardi JR, Castaneda-Corral G, et al. Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain. Pain. 2011;152(11):2564–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Lozano-Ondoua AN, Symons-Liguori AM, Vanderah TW. Cancer-induced bone pain: mechanisms and models. Neurosci Lett. 2013. 557 Pt A:52–9.

    Google Scholar 

  63. Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl 4):iv166-iv191.

    PubMed  Google Scholar 

  64. Mulvey MR, Rolke R, Klepstad P, et al. Confirming neuropathic pain in cancer patients: applying the NeuPSIG grading system in clinical practice and clinical research. Pain. 2014;155(5):859–63.

    Article  PubMed  Google Scholar 

  65. Tomotsuka N, Kaku R, Obata N, et al. Up-regulation of brain-derived neurotrophic factor in the dorsal root ganglion of the rat bone cancer pain model. J Pain Res. 2014;7:415–23.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Wong H, Hossain S, Cairns BE. Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation. Eur J Pain. 2017;21(10):1732–42.

    Article  CAS  PubMed  Google Scholar 

  67. Schirrmacher R, Bailey JJ, Mossine AV, et al. Radioligands for tropomyosin receptor kinase (Trk) positron emission tomography imaging. Pharmaceuticals (Basel). 2019;12(1)

    Google Scholar 

  68. Bailey JJ, Schirrmacher R, Farrell K, et al. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010–2016 – part II. Expert Opin Ther Pat. 2017;27(7):831–49.

    Article  CAS  PubMed  Google Scholar 

  69. Echeverria PC, Picard D. Molecular chaperones, essential partners of steroid hormone receptors for activity and mobility. Biochim Biophys Acta. 2010;1803(6):641–9.

    Article  CAS  PubMed  Google Scholar 

  70. Gaali S, Kirschner A, Cuboni S, et al. Selective inhibitors of the FK506-binding protein 51 by induced fit. Nat Chem Biol. 2015;11(1):33–7.

    Article  CAS  PubMed  Google Scholar 

  71. Yu HM, Wang Q, Sun WB. Silencing of FKBP51 alleviates the mechanical pain threshold, inhibits DRG inflammatory factors and pain mediators through the NF-kappaB signaling pathway. Gene. 2017;627:169–75.

    Article  CAS  PubMed  Google Scholar 

  72. Zhang L, Yang W, Tao K, et al. Sustained local release of NGF from a Chitosan-Sericin composite scaffold for treating chronic nerve compression. ACS Appl Mater Interfaces. 2017;9(4):3432–44.

    Article  CAS  PubMed  Google Scholar 

  73. He XL, Garcia KC. Structure of nerve growth factor complexed with the shared neurotrophin receptor p75. Science. 2004;304(5672):870–5.

    Article  CAS  PubMed  Google Scholar 

  74. Eibl JK, Chapelsky SA, Ross GM. Multipotent neurotrophin antagonist targets brain-derived neurotrophic factor and nerve growth factor. J Pharmacol Exp Ther. 2010;332(2):446–54.

    Article  CAS  PubMed  Google Scholar 

  75. Norman BH, McDermott JS. Targeting the Nerve Growth Factor (NGF) pathway in drug discovery. Potential applications to new therapies for chronic pain. J Med Chem. 2017;60(1):66–88.

    Article  CAS  PubMed  Google Scholar 

  76. Opar A. Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nat Rev Drug Discov. 2010;9(4):257–8.

    Article  CAS  PubMed  Google Scholar 

  77. Ashraf S, Bouhana KS, Pheneger J, et al. Selective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and joint damage in two rat models of inflammatory arthritis. Arthritis Res Ther. 2016;18(1):97.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Eibl JK, Strasser BC, Ross GM. Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor. Neurochem Int. 2012;61(8):1266–75.

    Article  CAS  PubMed  Google Scholar 

  79. Zhang X, Huang J, McNaughton PA. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J. 2005;24(24):4211–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Wang T, Yu D, Lamb ML. Trk kinase inhibitors as new treatments for cancer and pain. Expert Opin Ther Pat. 2009;19(3):305–19.

    Article  CAS  PubMed  Google Scholar 

  81. Loudon P, Siebenga P, Gorman D, et al. Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain models. Br J Clin Pharmacol. 2018;84(2):301–9.

    Article  CAS  PubMed  Google Scholar 

  82. Skerratt SE, Andrews M, Bagal SK, et al. The discovery of a potent, selective, and peripherally restricted pan-Trk inhibitor (PF-06273340) for the treatment of pain. J Med Chem. 2016;59(22):10084–99.

    Article  CAS  PubMed  Google Scholar 

  83. Carleton LA, Chakravarthy R, van der Sloot AM, et al. Generation of rationally-designed nerve growth factor (NGF) variants with receptor specificity. Biochem Biophys Res Commun. 2018;495(1):700–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The State University of New York at Binghamton (Binghamton University), Binghamton, NY, USA

    Alfred Malomo Jr

  2. University of Rochester School of Medicine and Dentistry, Department of Anesthesiology and Perioperative Medicine, Rochester, NY, USA

    Alfred Malomo Jr

  3. University of Rochester School of Medicine and Dentistry, Department of Anesthesiology, Rochester, NY, USA

    Daryl I. Smith

Authors
  1. Alfred Malomo Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daryl I. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daryl I. Smith .

Editor information

Editors and Affiliations

  1. School of Medicine, University of Rochester, Rochester, NY, USA

    Daryl I. Smith

  2. School of Medicine, University of Rochester, Rochester, NY, USA

    Hai Tran

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Malomo, A., Smith, D.I. (2022). Nerve Growth Factor and Neuropathic Pain. In: Smith, D.I., Tran, H. (eds) Pathogenesis of Neuropathic Pain. Springer, Cham. https://doi.org/10.1007/978-3-030-91455-4_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-91455-4_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-91454-7

  • Online ISBN: 978-3-030-91455-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation